Business
Denali Therapeutics Inc.: 4 This report contains estimates, projections and other information concerning our industry, our business and the markets for our product candidates.
Revenue was $0, while Net income decreased 21.2% to ($512.5M).
The read at a glance✓ Audited against SEC data
- Scale — FY2025 revenue $0Watch
- Profitability — Net income ($512.5M)Watch
- Cash generation — Free cash flow ($422.1M)Note
- Accounting — Formula distress score · manipulation and earnings-quality screens not computedWatch
- Insiders — 0 buys; 5 sells in 365 daysNote
- Capital — Comparable payout data unavailableNote
Where the revenue comes from
Fiscal 2025, as Denali Therapeutics Inc. reports it. History and quarterly detail are in the app.
- Related Party$295.5M
- ATV Abeta Option Material Right$293.9M
- Biogen$293.9M
- Sanofi$100.0M
- Collaborative Arrangement$100.0M
Latest filings
- 10-Q · Quarterly report2026-08-06
- 8-K · Company announcement2026-08-06
- 8-K · Company announcement2026-07-28
- 8-K · Company announcement2026-06-18
- 8-K · Company announcement2026-06-04
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about Denali Therapeutics Inc., every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.